NASDAQ:BEAM

Beam Therapeutics Stock Insider Trading

etoro logo Buy BEAM
*Your capital is at risk
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026

Beam Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -62.52. In total, the insiders bought 1.65M and sold 3.05M BEAM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-62.52
Buy 1.65M shares
Sell 3.05M shares
51% Buy Activity
Negligible or No Correlation
Buy Signal Low Confidence
Mar 31, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -62.52.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Apr 01, 2026
Sell
Common Stock
S-Sale
Ciaramella Giuseppe
President
CEO / President 11 810
Value: $290.3K
Apr 01, 2026
Sell
Common Stock
S-Sale
Bellon Christine
Chief Legal Officer
Officer 5 956
Value: $146.4K
Apr 01, 2026
Sell
Common Stock
S-Sale
Cavanagh Bethany J
SVP, Finance And Treasurer
Officer 3 242
Value: $79.7K
Apr 01, 2026
Sell
Common Stock
S-Sale
Simon Amy
Chief Medical Officer
Officer 6 700
Value: $164.7K
Apr 01, 2026
Sell
Common Stock
S-Sale
Evans John M.
CEO
CEO / President 30 078
Value: $739.3K
Mar 31, 2026
Buy
Common Stock
A-Award
Bellon Christine
Chief Legal Officer
Officer 20 000
Value: $476.6K
Mar 31, 2026
Buy
Common Stock
A-Award
Emany Sravan Kumar
Chief Financial Officer
C-Suite Officer 31 750
Value: $756.6K
Mar 31, 2026
Buy
Common Stock
A-Award
Ciaramella Giuseppe
President
CEO / President 40 000
Value: $953.2K
Mar 31, 2026
Buy
Common Stock
A-Award
Cavanagh Bethany J
SVP, Finance And Treasurer
Officer 20 000
Value: $476.6K
Mar 31, 2026
Buy
Common Stock
A-Award
Simon Amy
Chief Medical Officer
Officer 31 750
Value: $756.6K
Mar 31, 2026
Buy
Common Stock
A-Award
Evans John M.
CEO
CEO / President 90 000
Value: $2.14M
Mar 31, 2026
Buy
Common Stock
M-Exempt
Evans John M.
CEO
CEO / President 25 000
Value: $16.8K
Mar 31, 2026
Sell
Common Stock
S-Sale
Evans John M.
CEO
CEO / President 25 000
Value: $569.1K
Mar 31, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Evans John M.
CEO
CEO / President 25 000
Value: $16.8K
Mar 30, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Evans John M.
CEO
CEO / President 25 000
Value: $16.8K
Mar 30, 2026
Sell
Common Stock
S-Sale
Evans John M.
CEO
CEO / President 25 000
Value: $559.2K
Feb 24, 2026
Buy
Common Stock
M-Exempt
Ciaramella Giuseppe
President
CEO / President 35 000
Value: $595.0K
Feb 24, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Ciaramella Giuseppe
President
CEO / President 35 000
Value: $595.0K
Feb 24, 2026
Sell
Common Stock
S-Sale
Ciaramella Giuseppe
President
CEO / President 35 000
Value: $1.12M
Jan 31, 2026
Buy
Stock Option (Right to Buy)
A-Award
Simon Amy
Chief Medical Officer
Officer 88 500
Value: $2.44M
Jan 31, 2026
Buy
Stock Option (Right to Buy)
A-Award
Bellon Christine
Chief Legal Officer
Officer 40 000
Value: $1.10M
Jan 31, 2026
Buy
Stock Option (Right to Buy)
A-Award
Emany Sravan Kumar
Chief Financial Officer
C-Suite Officer 63 500
Value: $1.75M
Jan 31, 2026
Buy
Stock Option (Right to Buy)
A-Award
Ciaramella Giuseppe
President
CEO / President 80 000
Value: $2.21M
Jan 31, 2026
Buy
Stock Option (Right to Buy)
A-Award
Cavanagh Bethany J
SVP, Finance And Treasurer
Officer 40 000
Value: $1.10M
Jan 31, 2026
Buy
Stock Option (Right to Buy)
A-Award
Evans John M.
CEO
CEO / President 180 000
Value: $4.97M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT BEAM THERAPEUTICS INC.
Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE